FDA accepts request for a pre-IND meeting on EW-001 CAR-T therapy

AdAlta CEO and Managing Director, Dr Tim Oldham said: “The FDA agreeing to meet us is the headline. What matters more is what it took to reach the point where we could request the meeting. Our team has worked through hundreds of documents from SHcell covering how EW-001 is made, how it is tested and how it has performed in patients in China. We have worked with some of Australia’s most experienced CAR-T and mesothelioma clinicians to turn that into a draft Phase 1 clinical trial protocol. And we have worked alongside Cell Therapies to finalise manufacturing technology transfer and optimisation plans. A pre-IND briefing document is only possible once all of those pieces exist and fit together, so this is a milestone for the whole program and for our partners, not just for our regulatory team. Now, consistent with our capital efficient approach, we get to test our thinking with the world’s most experienced regulator of cell therapies before we commit to the costliest parts of the program.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib